RxDoctor Payments Data

Michael Hirsch, DO

Family Medicine · Pembroke Pines, FLNPI 1912984220

Payments from drug & device makers

$9,962in general payments, 2019–2025

Across 559 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$962
  • Pfizer$804
  • AstraZeneca$783
  • Amgen$769
  • Amarin Pharma, Inc.$760
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$9,921100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,962 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$106,313
Medicare patients
176
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$75,104
OzempicSemaglutide62$61,063
EliquisApixaban43$53,797
JanuviaSitagliptin Phosphate36$44,596
FarxigaDapagliflozin Propanediol40$41,991
VascepaIcosapent Ethyl82$39,816
MounjaroTirzepatide34$35,908
ProliaDenosumab20$34,321
JanumetSitagliptin Phos/Metformin Hcl35$31,718
TradjentaLinagliptin23$20,111
XareltoRivaroxaban15$19,710
EntrestoSacubitril/Valsartan19$18,757
Janumet XrSitagliptin Phos/Metformin Hcl16$16,604
LinzessLinaclotide25$15,018
ProcritEpoetin Alfa22$12,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$232$95,21593 claims
MerckJanuvia, Janumet, Janumet Xr$141$92,91787 claims
Novo NordiskOzempic$1,348$61,06362 claims
PfizerEliquis$804$53,79743 claims
Lilly USA, LLCMounjaro, Trulicity$962$46,11746 claims
AstraZenecaFarxiga, Symbicort$783$44,66852 claims
AmgenProlia$769$34,32120 claims
Johnson & JohnsonXarelto, Procrit$180$31,82237 claims
NovartisEntresto$152$18,75719 claims
AbbVieLinzess, Synthroid$673$17,58145 claims
Sanofi-aventis U.S. LLCMultaq$48$12,03811 claims
GSKArexvy, Shingrix$589$8,85532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →